Innovent Biologics, Inc. (HKG:1801)
Hong Kong · Delayed Price · Currency is HKD 98.05
+2.15 (2.24%)
Sep 30, 2026, 4:08 PM HKT
Innovent Biologics Stock Forecast
Stock Price Forecast
According to 30 analysts polled by S&P Global, Innovent Biologics stock has a consensus rating of "Strong Buy" and an average price target of $129.29. The average 1-year stock price forecast is 31.86% higher than the current stock price, while the lowest is $94.45 (-3.67%) and the highest is $150.16 (+53.15%).
Price Target: $129.29 (+31.86%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Innovent Biologics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 22 | 22 | 22 | 21 | 20 | 21 |
| Buy | 5 | 6 | 6 | 6 | 7 | 7 |
| Hold | 2 | 2 | 1 | 1 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 29 | 30 | 29 | 28 | 29 | 30 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
Unknown Analyst Bernstein No rating | Bernstein | Buy Maintains $128.00 | Buy | Maintains | $128.00 | +30.55% | Sep 22, 2026 |
Unknown Analyst Citic Securities No rating | Citic Securities | Buy Maintains $125.00 | Buy | Maintains | $125.00 | +27.49% | Sep 17, 2026 |
| DBS | DBS | Buy Reiterates $144.00 | Buy | Reiterates | $144.00 | +46.86% | Sep 14, 2026 |
Unknown Analyst Huatai Securities No rating | Huatai Securities | Buy Maintains $129.54 | Buy | Maintains | $129.54 | +32.12% | Sep 13, 2026 |
Unknown Analyst BOCOM International Holdings Company No rating | BOCOM International Holdings Company | Buy Maintains $118.00 → $129.00 | Buy | Maintains | $118.00 → $129.00 | +31.57% | Sep 3, 2026 |
Financial Forecast
Revenue This Year
18.56B
from 13.04B
Increased by 42.30%
Revenue Next Year
23.00B
from 18.56B
Increased by 23.96%
EPS This Year
1.42
from 0.99
Increased by 43.06%
EPS Next Year
2.16
from 1.42
Increased by 52.47%
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is CNY.